Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery

This study has been terminated.
(The study lost funding.)
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00880542
First received: April 10, 2009
Last updated: July 27, 2012
Last verified: July 2012
  Purpose

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as ifosfamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with ifosfamide may kill more tumor cells.

PURPOSE: This phase II trial is studying the side effects of giving sorafenib together with ifosfamide and to see how well it works in treating patients with high-grade soft tissue sarcoma or bone sarcoma that can be removed by surgery.


Condition Intervention Phase
Sarcoma
Drug: sorafenib
Drug: Ifosfamide
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Sorafenib and Ifosfamide as a Treatment for Patients With Sarcoma

Resource links provided by NLM:


Further study details as provided by Jonsson Comprehensive Cancer Center:

Primary Outcome Measures:
  • Using PET/CT Scan to Measure Safety, Toxicity, and Efficacy of Neoadjuvant Sorafenib Tosylate and Ifosfamide in Patients With Resectable High-grade Soft Tissue or Bone Sarcoma. [ Time Frame: Participants were followed for duration of study, an average of 1 year. ] [ Designated as safety issue: Yes ]
    After cycle 1, a limited PET/CT scan of the affected site will be performed to assess response to sorafenib treatment alone. After cycle 3, prior to surgery, a limited PET/CT scan of the affected site will be performed to assess response to the combination sorafenib and ifosfamide treatment.


Secondary Outcome Measures:
  • Local and Distant Recurrence-free Survival [ Time Frame: conclusion of study ] [ Designated as safety issue: No ]

Enrollment: 7
Study Start Date: August 2008
Primary Completion Date: November 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sorafenib + Ifosfamide

* Neoadjuvant therapy: Patients receive oral sorafenib tosylate twice daily on days 1-14 in course 1. Patients then receive oral sorafenib tosylate twice daily on days 1-28 and ifosfamide IV continuously on days 1-7 in courses 2 and 3. Treatment repeats every 14-28 days* for 3 courses.

NOTE: *Course 1 is 14 days in duration; courses 2 and 3 are 28 days in duration.

  • Surgery: At least 1 week after the completion of neoadjuvant therapy, patients undergo surgery.
  • Adjuvant therapy: Beginning ≥ 3 weeks after surgery, patients who respond to neoadjuvant therapy receive oral sorafenib twice daily for 6 months. Patients also receive 2 courses of ifosfamide as in courses 2 and 3 of neoadjuvant therapy.
Drug: sorafenib
Patients with sarcoma who have resectable disease will be treated with neoadjuvant sorafenib and ifosfamide. PET/CT will be used to assess the metabolic and radiographic response to therapy.
Drug: Ifosfamide
Patients with sarcoma who have resectable disease will be treated with neoadjuvant ifosfamide and sorafenib. PET/CT will be used to assess the metabolic and radiographic response to therapy.

Detailed Description:

OBJECTIVES:

Primary

  • Assess the safety, toxicity, and efficacy of neoadjuvant sorafenib tosylate and ifosfamide in patients with resectable high-grade soft tissue or bone sarcoma.

Secondary

  • Assess the long-term efficacy or impact of therapy in these patients, in terms of the duration of local recurrence-free survival, distant recurrence-free survival, and disease-specific survival.

OUTLINE:

  • Neoadjuvant therapy: Patients receive oral sorafenib tosylate twice daily on days 1-14 in course 1. Patients then receive oral sorafenib tosylate twice daily on days 1-28 and ifosfamide IV continuously on days 1-7 in courses 2 and 3. Treatment repeats every 14-28 days* for 3 courses.

NOTE: *Course 1 is 14 days in duration; courses 2 and 3 are 28 days in duration.

  • Surgery: At least 1 week after the completion of neoadjuvant therapy, patients undergo surgery.
  • Adjuvant therapy: Beginning ≥ 3 weeks after surgery, patients who respond to neoadjuvant therapy receive oral sorafenib twice daily for 6 months. Patients also receive 2 courses of ifosfamide as in courses 2 and 3 of neoadjuvant therapy.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pathologically confirmed high grade sarcoma of the soft tissue or bone
  • participants Identified as a proper candidate for ifosfamide-based neoadjuvant therapy
  • candidates must have operable disease for which a resection is planned
  • ECOG performance status 0-1
  • Hemoglobin ≥ 9.0 g/dL
  • ANC ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • ALT and AST ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver involvement)
  • INR < 1.5 or PT/PTT normal.Concurrent anticoagulation therapy with warfarin or heparin allowed
  • Creatinine ≤ 1.5 times ULN
  • women of childbearing potential must have negative pregnancy test performed within 7 days prior to start of treatment.
  • Fertile patients must use effective contraception during and for ≥ 2 weeks after completion of study therapy.
  • A signed informed consent must be obtained prior to any study specific procedures.

Exclusion Criteria:

  • known HIV infection
  • chronic hepatitis B or C infection
  • clinically active serious infection > CTCAE grade 2
  • NYHA class III or IV congestive heart failure
  • unstable angina (i.e., anginal symptoms at rest) or new onset angina within the past 3 months
  • myocardial infarction within the past 6 months
  • cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
  • uncontrolled hypertension (i.e., systolic blood pressure [BP] > 150 mm Hg or diastolic BP > 90 mm Hg) despite optimal medical management
  • thrombolic or embolic events (e.g., cerebrovascular accident, including transient ischemic attacks) within the past 6 months
  • pulmonary hemorrhage or bleeding event ≥ CTCAE grade 2 within the past 4 weeks
  • other hemorrhage or bleeding event ≥ CTCAE grade 3 within the past 4 weeks
  • Any condition that would impair the ability to swallow whole pills
  • malabsorption problem
  • Any known severe hypersensitivity to sorafenib tosylate or any of its excipients
  • known or suspected allergy to sorafenib tosylate or any agent given in this study
  • serious nonhealing wound, ulcer, or bone fracture
  • evidence or history of bleeding diathesis or coagulopathy
  • significant traumatic injury within the past 4 weeks
  • major surgery or open biopsy within 4 weeks of starting treatment
  • Concomitant St. John's wort or rifampin
  • KNown brain metastases. Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude brain metastases.
  • any condition that impairs patients' ability to swallow pills
  • any malabsorption problem
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00880542

Locations
United States, California
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California, United States, 90095-1781
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
Investigators
Principal Investigator: William Tap, MD Jonsson Comprehensive Cancer Center
  More Information

No publications provided

Responsible Party: Jonsson Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT00880542     History of Changes
Other Study ID Numbers: CDR0000633030, P30CA016042, UCLA-0704086, BAYER-UCLA-0704086, ONYX-UCLA-0704086
Study First Received: April 10, 2009
Results First Received: April 13, 2011
Last Updated: July 27, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Jonsson Comprehensive Cancer Center:
localized osteosarcoma
stage II adult soft tissue sarcoma
stage III adult soft tissue sarcoma

Additional relevant MeSH terms:
Sarcoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Connective and Soft Tissue
Ifosfamide
Isophosphamide mustard
Sorafenib
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on October 23, 2014